Category survey

Plasticity circuits in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

LISPRO, an ionic cocrystal of lithium, as a potential novel treatment for Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

SMALL MOLECULE THERAPY FOR ALZHEIMERS DISEASE Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimers therapy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Amyloid ion channels to design therapeutics for neurodegenerative diseases Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Novel Drug Discovery for AD Targeting Ryanodine Calcium Channels Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mechanism of IL-1 Dependent A-beta Plaque Clearance in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Pleiotropy GWAS of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Administrative Supplement: Neurobiological role of MicroRNA in Alzheimers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Coordinating Center for Genetics and Genomics of Alzheimers Disease (CGAD) Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Optimization and preclinical development of soluble gamma-secretase modulators for AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Characterization of ATXN1 in APP processing and AD pathogenesis Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mint Adaptor Proteins in APP Binding and Processing Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Alzheimers BACE1 inhibition regulates neuronal contactin function Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Immune-Mediated Mechanisms underlying CNS Abeta Clearance Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Roles of SN27 in regulating glutamate receptors during neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Novel roles by glutamatergic receptors in the synaptic effects of beta amyloid Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

STALLED CAPILLARY FLOW: A NOVEL MECHANISM FOR HYPOPERFUSION IN ALZHEIMER DISEASE Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

ApoE and LRP1 in brain insulin signaling and glucose metabolism (Competitive Renewal) Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Plasticity circuits in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Targeting a Novel Regulator of Brain Aging and Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mechanisms of resistance to cognitive decline in AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Inhibition of BACE1 for benefiting Alzheimers patients Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

APP Regulates Brain and Adipose Changes in Obesity Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Fyn Inhibition by AZD0530 for Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Development of a PET Tracer Selective for Cerebral Amyloid Angiopathy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Characterizing the glymphatic peri-vascular connectome and its disruption in AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Pleiotropic and Interaction Effects on Alzheimers disease Risk and Progression Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of the TOMM40 poly-T variant in the pathogenesis of Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

RNA splicing dysfunction in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Identification and characterization of AD risk networks using multi-dimensional omics data Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Genome-wide Profiling of Brain DNA Hydroxymethylome in Alzheimer’s Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Characterization of Alzheimers Mutations in ADAM10. Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

IDENTIFYING RARE VARIANTS THAT INCREASE RISK FOR ALZHEIMERS DISEASE Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Genome wide analysis of LXR binding – metabolic and epigenetic regulation in AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Functional Validation of the CD2AP Susceptibility Network in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experiences Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Imaging Genomics Based Brain Disease Prediction Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Neurobiological Role of MicroRNA in Alzheimers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Higher Order Chromatin and Genetic Risk for Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Genome Wide Analysis LXR Binding-Metabolic and Epigenetic Regulation in AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp) Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Molecular Phenotyping in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

African Ancestry and the Genomic Architecture of AD and Other Common Neurodegenerative Disease Neuropathologies Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Lewy Body Dementia Biomarkers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Identification of Functional Genomic Variants in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Imaging tau, amyloid, and neurodegeneration in PPA Investments > €500k United States of America Alzheimer’s disease & other dementias 2016